TIDE revealed that immunotherapeutic nonresponders had elevated NEIL3 levels, indicating that NEIL3 may inhibit the response rate of NSCLC to immunotherapy (Figure 7(b)). This evidence concerns the gene NEIL3 and non-small cell lung carcinoma.